Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Alopecia areata usually presents as a few small bald patches in the head
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The presentations underscore the company’s deep expertise in dermatology and immunology
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Subscribe To Our Newsletter & Stay Updated
